Posters

Nov 2021

SITC – Late Breaking Abstract

Final results from AIPAC: A phase IIb trial comparing eftilagimod alpha (soluble LAG-3 protein) in combination with weekly paclitaxel in HR+ HER2- MBC

Nov 2021

SITC

A Phase II study of eftilagimod alpha (soluble LAG-3 protein) and pembrolizumab in patients unselected for PD-L1 expression in first line metastatic head and neck squamous cell carcinoma (HNSCC)

Sep 2021

ESMO

Advanced safety and efficacy data from stratum D of the phase I INSIGHT platform trial evaluating feasibility and safety of eftilagimod alpha combined with avelumab in advanced solid tumors

Sep 2021

ESMO

Advanced safety and efficacy data from stratum D of the phase I INSIGHT platform trial evaluating feasibility and safety of eftilagimod alpha combined with avelumab in advanced solid tumors

Jun 2021

ASCO

Phase I INSIGHT platform trial: Advanced safety and efficacy data from stratum D evaluating feasibility and safety of eftilagimod alpha (soluble LAG-3 protein) combined with avelumab in advanced stage solid tumors.

Publications

LAG-3 induces tumor regression and antitumor immune responses in vivo.

Prigent, P., S. E. Mir, M. Dreano, and F. Triebel. 1999. Eur. J. Immunol. 29:3867.

Characterization of the major histocompatibility complex class II binding site on LAG-3 protein.

Huard, B., R. Mastrangeli, P. Prigent, D. Bruniquel, S. Donini, N. El-Tayar, B. Maigret, M. Dreano, and F. Triebel. 1997. Proc. Natl. Acad. Sci. USA 94:5744.

LAG-3, a novel lymphocyte activation gene closely related to CD4.

Triebel, F., S. Jitsukawa, E. Baixeras, S. Roman-Roman, C. Genevée, E. Viegas-Pequignot, and T. Hercend. 1990. J.Exp. Med. 171:1393.